Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

27 evidence topics · 30 sources

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.